Adocia grants Sanofi an exclusive right to negotiate a partnership on M1Pram for 10 million euros, and obtains a commitment from investors to raise a further 10 million euros.

The payment of 10 million euros to Adocia gives Sanofi the exclusive right to negotiate a worldwide partnership for the product.

M1Pram is an innovative combination of insulin and pramlintide developed by Adocia, which aims to become the reference rapid-acting insulin for people with diabetes and obesity.

Phase 2 clinical results in overweight and obese people with type 1 diabetes have shown exceptional weight loss with good glycemic control," says the company.

We are very pleased with this agreement with Sanofi. This commitment will enable us to accelerate the development of M1Pram while pursuing discussions with a view to a partnership. said Olivier Soula, Chief Executive Officer of Adocia.

Copyright (c) 2023 CercleFinance.com. All rights reserved.